[kee-toh-ROH-lack] Pregnancy Category: C Acular, Acular PF, Toradol, Toradol IM [Rx]
Classification: Nonsteroidal anti-inflammatory drug
Action/Kinetics: Possesses anti-inflammatory, analgesic, and antipyretic effects. Completely absorbed following IM use. Onset: Within 30 min. Maximum effect: 1-2 hr after IV or IM dosing. Duration: 4-6 hr. Peak plasma levels: 2.2-3.0 mcg/mL 50 min after a dose of 30 mg. tv2, terminal: 3.8-6.3 hr in young adults and 4.7-8.6 hr in geriatric clients. Over 99% is bound to plasma proteins. Metabolized in the liver with over 90% excreted in the urine and the remainder excreted in the feces.
Uses: PO: Short-term (up to 5 days) management of severe, acute pain that requires analgesia at the opiate level. Always initiate therapy with IV or IM followed by PO only as continuation treatment, if necessary. IM/IV: Ketorolac has been used with morphine and meperidine and shows an opioid-sharing effect. The combination can be used for breakthrough pain. Ophthalmic: Relieve itching caused by seasonal allergic conjunctivitis. Reduce ocular pain and photo phobia following inci-sional refractive surgery. Contraindications: Hypersensitivi-ty to the drug, incomplete or partial syndrome of nasal polyps, an-gioedema, and bronchospasm due to aspirin or other NSAIDs. Use in
clients with advanced renal impairment or in those at risk for renal failure due to volume depletion. Use in suspected or confirmed cardiovascular bleeding, hemorrhagic diathesis, or incomplete hemostasis and in those with a high risk of bleeding. Use as an obstetric preoperative medication or for obstetric analgesia. Routine use with other NSAIDs. Intrathecal or epidural administration. Use in labor and delivery. The ophthalmic solution should not be used in clients wearing soft contact lenses. Special Concerns: Use with caution in impaired hepatic or renal function, during lactation, in geriatric clients, and in clients on highdose salicylate regimens. The age, dosage, and duration of therapy should receive special consideration when using this drug. Safety and effectiveness have not been determined in children.
Additional Side Effects: CV: Vasodilation, pallor. Oral: Dry mouth, stomatitis. GI: GI pain, peptic ulcers, nausea, dyspepsia, flatulence, GI fullness, excessive thirst, GI bleeding (higher risk in geriatric clients), perforation. CNS: Headache, nervousness, abnormal thinking, depression, euphoria. Hypersensitivity: Bronchospasm, anaphylaxis. Miscellaneous: Purpura, asthma, abnormal vision, abnormal liver function.
Use of the ophthalmic solution: Transient stinging and burning following instillation, ocular irritation, allergic reactions, superficial ocular infections, superficial keratitis. Drug Interactions: Ketorolac may T plasma levels of salicylates due to i plasma protein binding. How Supplied: Injection: 15 mg/mL, 30 mg/mL; Ophthalmic solution: 0.5%; Tablet: 10 mg
Analgesic, single dose. Adults: less than 65 years of age: One 60-mg dose. Adults, over 65 years of age, in renal impair ment, or weight less than 50 kg:
Analgesic, multiple dose. Adults, less than 65 years of age: 30 mg q 6 hr, not to exceed 120 mg daily. Adults, over 65 years of age, in renal impairment, or weight less than 50 kg: 15 mg q 6 hr, not to exceed 60 mg daily.
Analgesic, single dose.
Adults, less than 65 years of age:
One 30-mg dose. Adults, over 65 years of age, in renal impairment, or weight less than 50 kg:
One 15-mg dose.
Transition from IV/IM to PO. Adults less than 65 years of age: 20
mg as a first PO dose for clients who received 60 mg IM single dose, 30 mg IV single dose, or 30 mg multiple dose IV/IM; then, 10 mg q 4-6 hr, not to exceed 40 mg in a 24-hr period.
Adults, over 65 years of age, in renal impairment, or weight less than 50 kg: 10 mg as a first PO dose for those who received a 30-mg IM single dose, a 15-mg IV single dose, or a 15-mg multiple dose IV/IM; then, 10 mg q 4-6 hr, not to exceed 40 mg in a 24-hr period.
• Ophthalmic Solution Seasonal allergic conjunctivitis.
1 gtt (0.25 mg) q.i.d. Efficacy has not been determined beyond 1 week of use.
Following cataract extraction. 1 gtt to the affected eye(s) q.i.d. beginning 24 hr after surgery and continuing for 2 weeks postoperatively.
Was this article helpful?
Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally